LL-37 10mg
Human Cathelicidin Antimicrobial Peptide for Immune and Wound Research
LL-37 is the only known human cathelicidin, providing broad-spectrum antimicrobial defense, modulating immune responses, and promoting wound healing. It plays a critical role in the innate immune system and has anti-biofilm, anti-inflammatory, and pro-angiogenic properties.
Human Cathelicidin Antimicrobial Peptide for Immune and Wound Research
LL-37 (hCAP-18/LL-37) disrupts bacterial membranes via electrostatic interactions, modulates Toll-like receptor signaling to balance innate immune responses, and stimulates angiogenesis and re-epithelialization in wound healing models.
As one of the most studied compounds in the recovery & healing research space, LL-37 has attracted sustained scientific interest across Antimicrobial research, Wound healing studies, Innate immunity research. Peer-reviewed evidence indicates that active against MRSA and drug-resistant pathogens, which has positioned LL-37 as a reference standard for researchers exploring antimicrobial research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
LL-37 Documented Benefits: 4 Documented Mechanisms
Broad-Spectrum Antimicrobial
Disrupts bacterial, fungal, and viral membranes across a wide spectrum of pathogens.
Biofilm Disruption
Penetrates and disrupts established bacterial biofilms resistant to conventional antibiotics.
Immune Modulation
Modulates TLR4 and TLR9 signaling to prevent excessive inflammation while maintaining pathogen clearance.
Wound Healing
Promotes keratinocyte migration, angiogenesis, and re-epithelialization in skin wound models.
How LL-37 Works: Molecular Mechanism & Pathway
Cationic helix-forming cathelicidin disrupting anionic bacterial membranes; simultaneously modulates TLR signaling and stimulates VEGF/EGF release for tissue repair.
The 4 primary research pathways identified for LL-37 — Broad-Spectrum Antimicrobial, Biofilm Disruption, Immune Modulation — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that anti-biofilm activity exceeds many antibiotics, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, LL-37's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
LL-37 is routinely studied alongside BPC-157 and KPV in recovery & healing-focused compound panels. Researchers investigating antimicrobial research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that stimulates wound closure in diabetic wound models has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All LL-37 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Active against MRSA and drug-resistant pathogens
- Anti-biofilm activity exceeds many antibiotics
- Stimulates wound closure in diabetic wound models
Ideal For
- Antimicrobial research
- Wound healing studies
- Innate immunity research
- Biofilm studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on LL-37. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Active against MRSA and drug-resistant pathogens
Anti-biofilm activity exceeds many antibiotics
Stimulates wound closure in diabetic wound models
Third-Party Verified Every Batch
Each vial of LL-37 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
